OPRX
BuyFull HouseAI neutralOptimizeRx Corporation · Healthcare · United States · $172M cap · $1.6M/day traded
$9.37 +0.8% · close 29 Oct · scored 30 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Report expected 5 Nov: the next-year EPS estimate has fallen 4.0% over the last 14 weeks.
As of 30 Oct 2026, MoatMap's StockRank for OptimizeRx Corporation (OPRX) is 80/100, ranked against 24,000+ stocks in 35 markets (Quality 68, Value 58, Momentum 51, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
OptimizeRx runs a digital platform that lets drug makers reach doctors and patients at the point of care. Its new partnership with The Trade Desk extends its reach to authenticated healthcare professionals on the open internet, and it keeps adding AI audience tools. The value score is attractive. However, this is a small company with a history of uneven growth and margins, and it relies on pharmaceutical marketing budgets. Momentum is weak, and there is no hard evidence yet that the partnership is lifting revenue.
ABOUT OPTIMIZERX CORPORATION
Read
OptimizeRx Corporation is a digital health technology company that connects pharmaceutical manufacturers with healthcare providers and patients at the point of care. The company's platform integrates directly into electronic health record (EHR) and e-prescribing workflows, creating a high-barrier-to-entry distribution network. Its competitive moat lies in its ability to deliver targeted clinical and financial information to physicians in real time.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62.5M | 71.5M | 92.1M | 109.4M | 20.6% | 98.7M | 96.2M | 106.6M | -1.3% |
| EPS | -0.64 | -1.03 | -1.10 | 0.28 | — | 0.24 | 0.23 | 0.28 | -0.3% |
| Shares | 17.1M | 18.2M | 18.5M | 18.8M | +9.9% | 18.8M | — | — | — |
| Debt | 0.2M | 36.8M | 33.2M | 26.1M | 381.1% | 19.5M | — | — | — |
| Equity | 126.1M | 126.6M | 117.0M | 128.3M | 0.6% | — | — | — | — |
| Op CF | 10.7M | -7.2M | 4.9M | 18.7M | 20.7% | 18.4M | — | — | — |
| Inv CF | -58.2M | -25.3M | -0.5M | 68.0K | — | — | — | — | — |
| Fin CF | -19.0M | 28.2M | -4.9M | -8.8M | — | — | — | — | — |
106% above its 52-week low and back above a rising 50-day average.
Swung more than 82% of stocks we rank over the past year (70% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OPRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OPRX | OptimizeRx Corporation(you) | $172M | 80 | Buy |
| AMWL | American Well Corporation | $231M | 74 | Buy |
| SPOK | Spok Holdings, Inc. | $215M | 96 | Strong Buy |
| CCLD | CareCloud, Inc. | $75M | 74 | Buy |
| NRC | NRC Health | $485M | 76 | Buy |
| DH | Definitive Healthcare Corp. | $115M | 62 | Hold |
| NURS.V | Hydreight Technologies Inc. | $123M | 57 | Hold |
| HCAT | Health Catalyst, Inc. | $127M | 49 | Hold |
| HSTM | HealthStream, Inc. | $1.1B | 80 | Strong Buy |
| PHR | Phreesia, Inc. | $788M | 72 | Buy |
Peer medians: ROE -30.5% · P/E 27.2x · Gross margin 63.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.